P3 Health Partners Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Loss per Share (Tables)

Loss per Share (Tables)

12 Months Ended

Dec. 31, 2022

Loss per Share

Schedule of computation of basic and diluted net loss per share


		Year Ended			December 3, 2021
		December 31,			through December 31,
		2022			2021
Net loss attributable to Class A common stockholders-basic and diluted		$	(270,127)		$	(10,081)

Weighted average Class A common shares outstanding-basic and diluted			41,579			41,579

Loss per share attributable to Class A common stockholders-basic and diluted		$	(6.50)		$	(0.24)

Schedule of potential dilutive securities excluded from the computation of diluted net loss per share their effect would have been anti-dilutive


		Year Ended			December 3, 2021
		December 31,			through December 31,
		2022			2021
Stock warrants⁽¹⁾			11,248			10,819
Stock options⁽¹⁾			3,402			—
Shares of Class V common stock⁽²⁾			201,972			202,025
Total			216,622			212,844

(1)	Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share

(2)	Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under application of the if-converted method.